

## SYNTHESIS OF MIMOSAMYCIN AND 5,8-DIHYDROXY-4,7-DIMETHOXY-2,6-DIMETHYLISOQUINOLINIUM IODIDE


Shinsuke Nakahara\* and Akinori Kubo

Meiji Pharmaceutical University

2-552-1, Noshio, Kiyose, Tokyo 204-8588, Japan


**Abstract** - The one-pot synthesis of mimosamycin utilizing the Polonovski reaction and a five-step synthesis of 5,8-dihydroxy-4,7-dimethoxy-2,6-dimethylisoquinolinium iodide (**7**) from known compound (**8**) are described.


The antimicrobial activity of mimosamycin (**1**), particularly against mycobacteria, was discovered in the culture filtrate of *Streptomyces lavendulae* in 1976,<sup>1a</sup> and the number of isoquinoline-5,8-dione antibiotics has increased rapidly since then.<sup>1</sup>




**1**: R=CH<sub>3</sub>, R'=OCH<sub>3</sub>  
(mimosamycin)

**4**: R=R'=SCH<sub>3</sub>  
(perfragilin B)




**2**: R=   
(renierone)

**3**: R=-NHCOCOCH<sub>3</sub>  
(mimocin)




**5**  
(cribrostatin 1)



**6**: X=HCO<sub>2</sub>  
**7**: X=I

In 1979, renierone (**2**) was isolated from the major metabolite of *Reniera* sp.<sup>1b</sup> Mimocin (**3**), isolated from a metabolite of *Streptomyces lavendulae*,<sup>1c</sup> contains a pyruvamide side chain in place of the angelate ester side chain of **2**. Perfragilin B (**4**), isolated from the Bryozoan *Biflustra perfragilis*,<sup>1e</sup> contains a methylthio ether group. Cribrostatin 1 (**5**), isolated from the marine sponge *Cribrochalina* sp.<sup>1f</sup> contains an amino group. In 1988, 5,8-dihydroxy-4,7-dimethoxy-2,6-dimethylisoquinolinium formate (**6**) was isolated from the culture broth of *Myxococcus Xanthus*<sup>2</sup> and the structure confirmed by comparison of its spectroscopic properties with those of 5-hydroxy-2-methylisoquinolinium methylsulfate. We have been interested in isoquinolinium formate (**6**) including the 5,8-dihydroxyisoquinoline skeleton, because the catalytic hydrogenation of 8-acetoxy-1-cyano-5-hydroxy-7-methoxy-6-methylisoquinoline caused the intramolecular transfer of the acyl group from the oxygen to the nitrogen atom, followed by air oxidation to produce the corresponding isoquinoline-5,8-dione.<sup>3</sup>


Four synthetic studies of mimosamycin have been conducted.<sup>4</sup> Recently, we reported the oxidative degradation of saframycin S to mimosamycin and mimocin.<sup>5</sup> Here, we describe the one-pot synthesis of mimosamycin and a five-step synthesis of 5,8-dihydroxy-4,7-dimethoxy-2,6-dimethylisoquinolinium iodide (**7**) from 7-methoxy-6-methyl-8-nitroisoquinoline-*N*-oxide (**8**). For the synthesis of mimosamycin, we used the Polonovski reaction<sup>6</sup> for the preparation of the key intermediate immonium salt. Into a stirred solution of tetrahydroisoquinoline-5,8-dione (**9**)<sup>7</sup> in CH<sub>2</sub>Cl<sub>2</sub> was added a solution of *m*-chloroperbenzoic acid (MCPBA) in CH<sub>2</sub>Cl<sub>2</sub> at -40°C. After stirring at this temperature for 0.5 h, acetic anhydride and triethylamine were added and the solution was stirred for an additional 1 h at 0°C. Work-up with ice-cold NaHCO<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> afforded mimosamycin (**1**) in 30% yield (Scheme 1). When pyridine was utilized instead of triethylamine, many spots were obtained on TLC; decreasing the yield of **1** to 4%. Synthetic **1** was identical to an authentic sample in terms of TLC behavior and spectroscopic properties.



i 85% MCPBA, CH<sub>2</sub>Cl<sub>2</sub>, -40 °C, 5 h ii (CH<sub>3</sub>CO)<sub>2</sub>O, TEA, 0 °C, 1 h


Scheme 1

The proposed mechanism is shown in Scheme 2. The immonium salt was formed in step B and air oxidation of the 5,8-dihydroxy compound to the 5,8-dione occurred during step E.



Scheme 2

The preparation of 5,8-dihydroxy-4,7-dimethoxy-2,6-dimethylisoquinolinium iodide (**7**) was conducted as shown in Scheme 3. Introduction of a hydroxyl group into the C-4 position of isoquinoline (**8**) was achieved using the procedure of Ochiai and Ikehara.<sup>8</sup>



a) i) TsCl, CHCl<sub>3</sub>, reflux, 2 h ii) KOH, EtOH, reflux, 2 h b) CH<sub>2</sub>N<sub>2</sub>, MeOH-ether, rt, 0.5 h c) 10% Pd-C, MeOH, rt, 4 h  
d) Fremy's salt, KH<sub>2</sub>PO<sub>4</sub>, acetone, 35%, 0.5 h e) i) 10% Pd-C, MeOH, rt, 1 h ii) MeI, rt, 1 h

Scheme 3

Treatment of 7-methoxy-6-methyl-8-nitroisoquinoline-*N*-oxide (**8**)<sup>9</sup> with tosyl chloride in CHCl<sub>3</sub> under reflux for 2 h, followed by potassium hydroxide in aqueous EtOH for 2 h, gave the 4-hydroxyisoquinoline (**10**) in 35% yield. Treatment of **10** with diazomethane in ether for 0.5 h afforded 4-methoxyisoquinoline (**11**) in 59% yield. Catalytic hydrogenation of **11** over 10% Pd-C

in MeOH afforded 8-aminoisoquinoline (**12**) in 65% yield. The oxidation of **12** with potassium nitrosodisulfonate (Fremy's salt)<sup>10</sup> furnished the isoquinoline-5,8-dione (**13**) in 46% yield. Finally, catalytic hydrogenation of **13** over 10% Pd-C in MeOH followed by methyl iodide treatment at room temperature for 1 h afforded 5,8-dihydroxy-4,7-dimethoxy-2,6-dimethylisoquinolinium iodide (**7**) in 66% yield.

In summary, mimosamycin was synthesized using the Polonovski reaction and a mechanism is proposed for the synthesis. 5,8-Dihydroxy-4,7-dimethoxy-2,6-dimethylisoquinolinium iodide (**7**) was synthesized from 7-methoxy-6-methyl-8-nitroisoquinoline-*N*-oxide (**8**) in five steps. Compound (**7**) includes a 5,8-dihydroxyisoquinoline skeleton but is stable in air at room temperature.

## EXPERIMENTAL

All melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. <sup>1</sup>H-NMR spectra at 100 MHz and 270 MHz were measured in CDCl<sub>3</sub> with tetramethylsilane as an internal standard. Anhydrous sodium sulfate was used for drying organic solvent extracts, and the solvent was removed with a rotary evaporator and finally under high vacuum. Column chromatography (flash chromatography) was performed with silica gel 60 (Merck, 230-400 mesh).

### Mimosamycin (**1**)

Into a stirred solution of tetrahydroisoquinoline-5,8-dione (**9**)<sup>7</sup> (45 mg, 0.2 mmol) in 2 mL of CH<sub>2</sub>Cl<sub>2</sub> was added at -40 °C a solution of *m*-chloroperbenzoic acid (MCPBA) (215 mg, 1.06 mmol) in 4 mL of CH<sub>2</sub>Cl<sub>2</sub>. After stirring at this temperature for 0.5 h acetic anhydride (0.1 mL, 1.06 mmol) and triethylamine (0.7 mL, 5.02 mmol) were added to the solution which is then stirred for additional 1 h at 0 °C. The whole was poured into 1% aqueous NaHCO<sub>3</sub> solution (30 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 10 mL). The extract was washed with brine, dried and concentrated. The residue was chromatographed (eluting with hexane-ethyl acetate 1 : 1) to afford mimosamycin (**1**) (14 mg, 30%). IR(KBr) cm<sup>-1</sup>: 1688, 1644, 1586. <sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ: 2.06(3H, s), 3.67(3H, s), 4.17(3H, s), 7.09(1H, s), 8.27(1H, s). <sup>13</sup>C-NMR(100 MHz, CDCl<sub>3</sub>) δ: 9.6, 38.4, 61.3, 111.3, 116.7, 133.1, 138.9, 142.1, 159.5, 162.8, 177.3, 183.5. Ms *m/z* (%): 233(M<sup>+</sup>, 100), 218(36), 205(31), 190(23).

### 4-Hydroxy-7-methoxy-6-methyl-8-nitroisoquinoline (**10**)

Tosyl chloride (572 mg, 3 mmol) was added in portions to a solution of 7-methoxy-6-methyl-8-nitroisoquinoline-*N*-oxide (**8**) (234 mg, 1 mmol) in 3 mL of CHCl<sub>3</sub> with stirring at 0 °C. The solution was boiled under reflux for 2 h and then the solvent was removed under reduced pressure. The residue was dissolved in 20 mL of EtOH and 20 mL of 6% aqueous KOH solution was added. The solution was boiled under reflux for 2 h, then diluted with water, adjusted to pH 5~6 with NH<sub>4</sub>Cl and extracted with ethyl acetate (3 x 50 mL). The extract was washed with brine, dried and concentrated. The residue was chromatographed (eluting with hexane-ethyl acetate 1 : 1) to afford 4-hydroxyisoquinoline (**10**) (82 mg, 35%). mp 202~202.5 °C (yellow prisms from

MeOH). *Anal.* Calcd for C<sub>11</sub>H<sub>10</sub>N<sub>2</sub>O<sub>4</sub>: C, 56.41; H, 4.30; N, 11.96. Found: C, 56.41; H, 4.29; N, 11.95. IR(KBr) cm<sup>-1</sup>: 3440, 1532, 1358. <sup>1</sup>H-NMR(CDCl<sub>3</sub>+ CD<sub>3</sub>OD) : 2.55(3H, s), 3.99(3H, s), 8.04(1H, s), 8.24(1H, s), 8.56(1H, s). Ms *m/z* (%): 234(M<sup>+</sup>, 100), 130(32), 103(28).

#### **4,7-Dimethoxy-6-methyl-8-nitroisoquinoline (11)**

4-Hydroxyisoquinoline (**10**)(456 mg, 1.95 mmol) in 5 mL of MeOH was added to an ether solution containing excess of CH<sub>2</sub>N<sub>2</sub> and the mixture was stirred at rt for 0.5 h. The solvent was evaporated and the residue was chromatographed (eluting with hexane-ethyl acetate 2 : 1) to afford **11** (285 mg, 59%). mp 112~113 (light yellow needles from CHCl<sub>3</sub>-hexane). *Anal.* Calcd for C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>: C, 58.06; H, 4.87; N, 11.29. Found: C, 58.03; H, 4.80; N, 11.28. IR(KBr) cm<sup>-1</sup>: 1530, 1362. <sup>1</sup>H-NMR(CDCl<sub>3</sub>) : 2.41(3H, s), 3.82(3H, s), 3.91(3H, s), 8.11(1H, s), 8.14(1H, s), 8.68(1H, s). Ms *m/z* (%): 248(M<sup>+</sup>, 100), 188(9), 172(8), 144(10).

#### **8-Amino-4,7-dimethoxy-6-methylisoquinoline (12)**

4,7-Dimethoxy-6-methyl-8-nitroisoquinoline (**11**)(280 mg, 1.13 mmol) in MeOH (30 mL) was hydrogenated at 1 atm for 4 h using 10% Pd-C (100 mg) as a catalyst. The catalyst was filtered off, the solvent was removed and the residue was chromatographed (eluting with hexane-ethyl acetate 1 : 1) to afford 8-aminoisoquinoline (**12**) (160 mg, 65%). mp 198~199 (light yellow prisms from CHCl<sub>3</sub>-hexane). *Anal.* Calcd for C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>: C, 66.03; H, 6.47; N, 12.84. Found: C, 65.84; H, 6.52; N, 12.72. IR(KBr) cm<sup>-1</sup>: 3396. <sup>1</sup>H-NMR(CDCl<sub>3</sub>) : 2.43(3H, s), 3.78(3H, s), 3.98(3H, s), 4.64~4.06(2H, br s), 7.40(1H, s), 7.93(1H, s), 8.84(1H, s). Ms *m/z* (%): 218(M<sup>+</sup>, 70), 203(100), 175(32).

#### **4,7-Dimethoxy-6-methyl-5,8-dihydroisoquinoline-5,8-dione (13)**

A solution of Fremy's salt (0.3 g, 1.1 mmol) in 1/15 aq. KH<sub>2</sub>PO<sub>4</sub> (12.5 mL) was added to 8-amino-4,7-dimethoxy-6-methylisoquinoline (**12**)(36 mg, 0.16 mmol) in acetone (1.2 mL). The mixture was stirred at 35 for 0.5 h, diluted with water, made alkaline with sat. NaHCO<sub>3</sub> and extracted with CHCl<sub>3</sub> (3 x 20 mL). The extract was washed with brine, dried and concentrated. The residue was chromatographed (eluting with hexane-ethyl acetate 4 : 1) to afford *p*-quinone (**13**) (17 mg, 46%). mp 150~151 (yellow needles from CHCl<sub>3</sub>-MeOH). *Anal.* Calcd for C<sub>12</sub>H<sub>11</sub>NO<sub>4</sub>: C, 61.80; H, 4.75; N, 6.01. Found: C, 61.81; H, 4.63; N, 5.99. IR(KBr) cm<sup>-1</sup>: 1670, 1656. <sup>1</sup>H-NMR(CDCl<sub>3</sub>) : 2.06(3H, s), 4.13(6H, s), 8.74(1H, s), 8.92(1H, s). Ms *m/z* (%): 233(M<sup>+</sup>, 100), 218(28), 190(29).

#### **5,8-Dihydroxy-4,7-dimethoxy-2,6-dimethylisoquinolinium iodide (7)**

4,7-Dimethoxy-6-methyl-5,8-dihydroisoquinoline-5,8-dione (**13**) (15 mg, 0.064 mmol) in MeOH (3 mL) was hydrogenated at 1 atm for 1 h using 10% Pd-C (8 mg) as a catalyst. The catalyst was filtered off, the solvent was removed and methyl iodide (2.8 g, 20 mmol) was added. The solution was stirred at rt for 1 h, the precipitated crystals were collected and recrystallized from CHCl<sub>3</sub>-MeOH to give isoquinolinium iodide (**7**)(16 mg, 66%) as yellow needles melting at 122~124. HRMS Calcd for C<sub>12</sub>H<sub>13</sub>NO<sub>4</sub>: 235.0845, Found: 235.0843. Ms *m/z* (%): 235(39), 220(28), 192(32), 142(100), 127(59). IR(KBr) cm<sup>-1</sup>: 3412. <sup>1</sup>H-NMR(CDCl<sub>3</sub>+CD<sub>3</sub>OD) : 2.38(3H, s), 3.84(3H, s), 4.21(3H, s), 4.40(3H, s), 7.98(1H, s), 9.30(1H, s). <sup>13</sup>C-NMR(67.5 Hz,

CDCl<sub>3</sub>+CD<sub>3</sub>OD) : 10.63, 48.83, 59.11, 61.50, 113.88, 115.46, 119.24, 131.45, 141.20, 143.07, 145.83, 148.66, 156.20.

## REFERENCES

- 1 a) T. Arai, K. Yazawa, Y. Mikami, A. Kubo, and K. Takahashi, *J. Antibiot.*, 1976, **29**, 398. b) D. E. McIntyre, D. J. Faulkner, D.V. Engen, and J. Clardy, *Tetrahedron Lett.*, **1979**, 4163. c) A. Kubo, S. Nakahara, R. Iwata, K. Takahashi, and T. Arai, *Tetrahedron Lett.*, 1980, **21**, 3207. d) J. M. Frincke and D. J. Faulkner, *J. Am. Chem. Soc.*, 1982, **104**, 265. e) F. J. Schmitz, F. S. DeGuzman, Y.-H. Choi, M. B. Hossain, S. K. Rizvi, and D. van der Helm, *Pure Appl. Chem.*, 1990, **62**, 1393. f) G. R. Pettit, J. C. Collins, D. L. Herald, D. L. Doubek, M. R. Boyd, J. M. Schmidt, J. N. A. Hooper, and L. P. Tackett, *Can. J. Chem.*, 1992, **70**, 1170. g) A. J. Blackman, C. E. Ralph, B. W. Skelton, and A. H. White, *Aust. J. Chem.*, 1993, **46**, 213. h) Y.-H. Choi, A. Park, F. J. Schmitz, and I. van Aitena, *J. Nat. Prod.*, 1993, **56**, 1431. i) A. Park and F. J. Schmitz, *Tetrahedron Lett.*, 1993, **34**, 3983. j) M. Kobayashi, S. R. Rao, R. Chavakula, and N. S. Sarma, *J. Chem. Res. (S)*, **1994**, 282. k) G. R. Pettit, J. C. Knight, J. C. Collins, D. L. Herald, R. K. Pettit, M. R. Boyd, and V. G. Young, *J. Nat. Prod.*, 2000, **63**, 793. l) G. R. Pettit, J. C. Collins, J. C. Knight, D. L. Herald, R. A. Nieman, M. D. Williams, and R. K. Pettit, *J. Nat. Prod.*, 2003, **66**, 544.
- 2 T. K. Wolfram, I. Herbert, W. Victor, R. Hans, and H. Gerhard, *Liebigs Ann. Chem.*, **1988**, 483.
- 3 S. Nakahara and A. Kubo, *Heterocycles*, 2003, **60**, 2717.
- 4 a) H. Fukuyama, H. Kurihara, T. Hata, C. Tamura, H. Mishima, A. Kubo, and T. Arai, *Tetrahedron Lett.*, 1977, 3825. b) A. Mckillop and S. P. Brown, *Synth. Commun.*, 1987, **17**, 657. c) K. A. Parker and D. A. Casteel, *J. Org. Chem.*, 1988, **53**, 2847. d) B. Kesteleyn and N. De Kimpe, *J. Org. Chem.*, 2000, **65**, 635.
- 5 N. Saito, Y. Koizumi, C. Tanaka, K. Suwanborirux, S. Amnuoypol, and A. Kubo, *Heterocycles*, 2003, **61**, 79.
- 6 P. Stutz and P. A. Stadler, *Tetrahedron Lett.*, **1973**, 5095.
- 7 S. Kitahara, S. Nakahara, Y. Koizumi, H. Muranishi, and A. Kubo, *Chem. Pharm. Bull.*, 1988, **36**, 3623.
- 8 E. Ochiai and M. Ikehara, *Pharm. Bull.*, 1955, **3**, 454.
- 9 A. Kubo, S. Nakahara, K. Inaba, and S. Kitahara, *Chem. Pharm. Bull.*, 1986, **34**, 4056.
- 10 H.-J. Teuber and M. Hasselbach, *Chem. Ber.*, 1959, **92**, 674.